I understand. We could have stuck to the original plan and be...

I understand. We could have stuck to the original plan and be further along on that path, but that would mean we would not have been able to advance the current strategy. A huge amount of things have been learnt about bisantrene since 2021 that have completely changed the value proposition of the drug. We could either choose to ignore this new value and stick to the original strategy, or change direction and have this effect the timelines.

I am curious what people would have preferred. Would people have preferred we just stuck with RC110 and all the limitations that come with this formulations, or should we have switched our attention to RC220 even though this effects the timelines?